Vaccination with JAK2-mutant- and CALR-mutant-derived peptides will probably induce tumor-specific immune responses that will be further enhanced by co-vaccination with anti-regulatory epitopes, such as PD-L1- and ARG1-derived epitopes. Here, JAK2 is linked to neoplasm.